Viral Interleukin-10-Engineered Autologous Hematopoietic Stem Cell Therapy: A Novel Gene Therapy Approach to Prevent Graft Rejection

Shashikumar K. Salgar, Dinghua Yang, Phillip Ruiz, Joshua Miller, Andreas G. Tzakis

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The Epstein-Barr virus-encoded protein BCRF1 (viral interleukin [vIL]-10) is a biologically active homologue of cellular interleukin (IL)-10. In this study, a novel gene therapy approach to prolong allograft survival was designed. Autologous (syngeneic) hematopoietic progenitor/stem cell-enriched (HSC; lineage-ve) population derived from CBA/J mouse bone marrow were transduced with retrovirus encoding vIL-10 gene (vIL-10-HSC), ex vivo; vIL-10-HSC were injected (4-6 X 106 cells intravenously) into lethally (9.5 Gy) or sublethally (4 Gy) irradiated CBA/J mice. Six weeks after vIL-10-HSC administration, vascular heterotopic heart (C57BL/6) transplantation was performed. Ex vivo, the vIL-10-HSC produced 5.4 ± 0.5 ng of vIL-10 protein/2 X 105 cells per 24 hr. In vivo, serum vIL-10 production was 187 ± 205 pg/ml during 3-10 weeks after vIL-10-HSC administration. Cardiac allograft survival was prolonged (p < 0.004) in lethally (71 ± 40 days) and sublethally (114 ± 15 days) irradiated mice that received vIL-10-HSC compared to controls that received unengineered (UE) HSC or vector DNA-engineered HSC (12-16 days). However, secondary skin graft (C57BL/6) survival was not prolonged in cardiac allograft-tolerant animals. In the vIL-10-HSC-administered group, graft histopathology demonstrated mild arteritis/venulitis (grade 0.7) and rejection (grade 1.0). Intragraft expression of costimulatory molecules (B7.1, B7.2), cytokines (IL-2, IL-4, mIL-10, interferon [IFN]-γ), and inducible nitric oxide synthase (iNOS) molecules was markedly lower in vIL-10-HSC-treated tolerant grafts that survived more than 100 days compared to vector DNA-HSC- or UE-HSC-treated controls. Furthermore, T lymphocytes derived from vIL-10-HSC-treated tolerant recipients demonstrated hyporeactivity to donor antigens in mixed lymphocyte cultures. Administration of autologous vIL-10-engineered HSC prior to organ transplantation prolonged cardiac allograft survival significantly.

Original languageEnglish
Pages (from-to)131-144
Number of pages14
JournalHuman Gene Therapy
Volume15
Issue number2
DOIs
StatePublished - Feb 1 2004

Fingerprint

Graft Rejection
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Genetic Therapy
Interleukin-10
Allografts
Inbred CBA Mouse
Transplants
Arteritis
Viral Genes
DNA
Organ Transplantation
Viral Proteins
Nitric Oxide Synthase Type II
Retroviridae
Human Herpesvirus 4
Interleukin-4
Interferons
Interleukin-2
Blood Vessels

ASJC Scopus subject areas

  • Genetics

Cite this

Viral Interleukin-10-Engineered Autologous Hematopoietic Stem Cell Therapy : A Novel Gene Therapy Approach to Prevent Graft Rejection. / Salgar, Shashikumar K.; Yang, Dinghua; Ruiz, Phillip; Miller, Joshua; Tzakis, Andreas G.

In: Human Gene Therapy, Vol. 15, No. 2, 01.02.2004, p. 131-144.

Research output: Contribution to journalArticle

Salgar, Shashikumar K. ; Yang, Dinghua ; Ruiz, Phillip ; Miller, Joshua ; Tzakis, Andreas G. / Viral Interleukin-10-Engineered Autologous Hematopoietic Stem Cell Therapy : A Novel Gene Therapy Approach to Prevent Graft Rejection. In: Human Gene Therapy. 2004 ; Vol. 15, No. 2. pp. 131-144.
@article{a4c8b95a5491457c8e2fad911f89a532,
title = "Viral Interleukin-10-Engineered Autologous Hematopoietic Stem Cell Therapy: A Novel Gene Therapy Approach to Prevent Graft Rejection",
abstract = "The Epstein-Barr virus-encoded protein BCRF1 (viral interleukin [vIL]-10) is a biologically active homologue of cellular interleukin (IL)-10. In this study, a novel gene therapy approach to prolong allograft survival was designed. Autologous (syngeneic) hematopoietic progenitor/stem cell-enriched (HSC; lineage-ve) population derived from CBA/J mouse bone marrow were transduced with retrovirus encoding vIL-10 gene (vIL-10-HSC), ex vivo; vIL-10-HSC were injected (4-6 X 106 cells intravenously) into lethally (9.5 Gy) or sublethally (4 Gy) irradiated CBA/J mice. Six weeks after vIL-10-HSC administration, vascular heterotopic heart (C57BL/6) transplantation was performed. Ex vivo, the vIL-10-HSC produced 5.4 ± 0.5 ng of vIL-10 protein/2 X 105 cells per 24 hr. In vivo, serum vIL-10 production was 187 ± 205 pg/ml during 3-10 weeks after vIL-10-HSC administration. Cardiac allograft survival was prolonged (p < 0.004) in lethally (71 ± 40 days) and sublethally (114 ± 15 days) irradiated mice that received vIL-10-HSC compared to controls that received unengineered (UE) HSC or vector DNA-engineered HSC (12-16 days). However, secondary skin graft (C57BL/6) survival was not prolonged in cardiac allograft-tolerant animals. In the vIL-10-HSC-administered group, graft histopathology demonstrated mild arteritis/venulitis (grade 0.7) and rejection (grade 1.0). Intragraft expression of costimulatory molecules (B7.1, B7.2), cytokines (IL-2, IL-4, mIL-10, interferon [IFN]-γ), and inducible nitric oxide synthase (iNOS) molecules was markedly lower in vIL-10-HSC-treated tolerant grafts that survived more than 100 days compared to vector DNA-HSC- or UE-HSC-treated controls. Furthermore, T lymphocytes derived from vIL-10-HSC-treated tolerant recipients demonstrated hyporeactivity to donor antigens in mixed lymphocyte cultures. Administration of autologous vIL-10-engineered HSC prior to organ transplantation prolonged cardiac allograft survival significantly.",
author = "Salgar, {Shashikumar K.} and Dinghua Yang and Phillip Ruiz and Joshua Miller and Tzakis, {Andreas G.}",
year = "2004",
month = "2",
day = "1",
doi = "10.1089/104303404772679940",
language = "English",
volume = "15",
pages = "131--144",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Viral Interleukin-10-Engineered Autologous Hematopoietic Stem Cell Therapy

T2 - A Novel Gene Therapy Approach to Prevent Graft Rejection

AU - Salgar, Shashikumar K.

AU - Yang, Dinghua

AU - Ruiz, Phillip

AU - Miller, Joshua

AU - Tzakis, Andreas G.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - The Epstein-Barr virus-encoded protein BCRF1 (viral interleukin [vIL]-10) is a biologically active homologue of cellular interleukin (IL)-10. In this study, a novel gene therapy approach to prolong allograft survival was designed. Autologous (syngeneic) hematopoietic progenitor/stem cell-enriched (HSC; lineage-ve) population derived from CBA/J mouse bone marrow were transduced with retrovirus encoding vIL-10 gene (vIL-10-HSC), ex vivo; vIL-10-HSC were injected (4-6 X 106 cells intravenously) into lethally (9.5 Gy) or sublethally (4 Gy) irradiated CBA/J mice. Six weeks after vIL-10-HSC administration, vascular heterotopic heart (C57BL/6) transplantation was performed. Ex vivo, the vIL-10-HSC produced 5.4 ± 0.5 ng of vIL-10 protein/2 X 105 cells per 24 hr. In vivo, serum vIL-10 production was 187 ± 205 pg/ml during 3-10 weeks after vIL-10-HSC administration. Cardiac allograft survival was prolonged (p < 0.004) in lethally (71 ± 40 days) and sublethally (114 ± 15 days) irradiated mice that received vIL-10-HSC compared to controls that received unengineered (UE) HSC or vector DNA-engineered HSC (12-16 days). However, secondary skin graft (C57BL/6) survival was not prolonged in cardiac allograft-tolerant animals. In the vIL-10-HSC-administered group, graft histopathology demonstrated mild arteritis/venulitis (grade 0.7) and rejection (grade 1.0). Intragraft expression of costimulatory molecules (B7.1, B7.2), cytokines (IL-2, IL-4, mIL-10, interferon [IFN]-γ), and inducible nitric oxide synthase (iNOS) molecules was markedly lower in vIL-10-HSC-treated tolerant grafts that survived more than 100 days compared to vector DNA-HSC- or UE-HSC-treated controls. Furthermore, T lymphocytes derived from vIL-10-HSC-treated tolerant recipients demonstrated hyporeactivity to donor antigens in mixed lymphocyte cultures. Administration of autologous vIL-10-engineered HSC prior to organ transplantation prolonged cardiac allograft survival significantly.

AB - The Epstein-Barr virus-encoded protein BCRF1 (viral interleukin [vIL]-10) is a biologically active homologue of cellular interleukin (IL)-10. In this study, a novel gene therapy approach to prolong allograft survival was designed. Autologous (syngeneic) hematopoietic progenitor/stem cell-enriched (HSC; lineage-ve) population derived from CBA/J mouse bone marrow were transduced with retrovirus encoding vIL-10 gene (vIL-10-HSC), ex vivo; vIL-10-HSC were injected (4-6 X 106 cells intravenously) into lethally (9.5 Gy) or sublethally (4 Gy) irradiated CBA/J mice. Six weeks after vIL-10-HSC administration, vascular heterotopic heart (C57BL/6) transplantation was performed. Ex vivo, the vIL-10-HSC produced 5.4 ± 0.5 ng of vIL-10 protein/2 X 105 cells per 24 hr. In vivo, serum vIL-10 production was 187 ± 205 pg/ml during 3-10 weeks after vIL-10-HSC administration. Cardiac allograft survival was prolonged (p < 0.004) in lethally (71 ± 40 days) and sublethally (114 ± 15 days) irradiated mice that received vIL-10-HSC compared to controls that received unengineered (UE) HSC or vector DNA-engineered HSC (12-16 days). However, secondary skin graft (C57BL/6) survival was not prolonged in cardiac allograft-tolerant animals. In the vIL-10-HSC-administered group, graft histopathology demonstrated mild arteritis/venulitis (grade 0.7) and rejection (grade 1.0). Intragraft expression of costimulatory molecules (B7.1, B7.2), cytokines (IL-2, IL-4, mIL-10, interferon [IFN]-γ), and inducible nitric oxide synthase (iNOS) molecules was markedly lower in vIL-10-HSC-treated tolerant grafts that survived more than 100 days compared to vector DNA-HSC- or UE-HSC-treated controls. Furthermore, T lymphocytes derived from vIL-10-HSC-treated tolerant recipients demonstrated hyporeactivity to donor antigens in mixed lymphocyte cultures. Administration of autologous vIL-10-engineered HSC prior to organ transplantation prolonged cardiac allograft survival significantly.

UR - http://www.scopus.com/inward/record.url?scp=1142309485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1142309485&partnerID=8YFLogxK

U2 - 10.1089/104303404772679940

DO - 10.1089/104303404772679940

M3 - Article

C2 - 14975186

AN - SCOPUS:1142309485

VL - 15

SP - 131

EP - 144

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 2

ER -